Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) shares traded up 10.1% on Friday . The company traded as high as $8.85 and last traded at $8.85. 187,289 shares were traded during trading, a decline of 53% from the average session volume of 396,758 shares. The stock had previously closed at $8.04.
Wall Street Analysts Forecast Growth
BCYC has been the topic of a number of analyst reports. Morgan Stanley set a $17.00 target price on shares of Bicycle Therapeutics and gave the stock an "equal weight" rating in a report on Monday, May 5th. Barclays cut their price target on shares of Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Needham & Company LLC reissued a "buy" rating and issued a $29.00 price target on shares of Bicycle Therapeutics in a research note on Friday, May 2nd. Royal Bank Of Canada cut their price target on shares of Bicycle Therapeutics from $32.00 to $25.00 and set an "outperform" rating for the company in a research note on Thursday, July 17th. Finally, B. Riley cut their price target on shares of Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $24.22.
View Our Latest Analysis on Bicycle Therapeutics
Bicycle Therapeutics Price Performance
The company has a market cap of $578.20 million, a P/E ratio of -2.66 and a beta of 1.41. The firm's 50-day moving average is $7.96 and its two-hundred day moving average is $9.59.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Bicycle Therapeutics had a negative return on equity of 25.54% and a negative net margin of 790.07%. The company had revenue of $9.98 million during the quarter, compared to the consensus estimate of $8.67 million. As a group, sell-side analysts expect that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. boosted its holdings in shares of Bicycle Therapeutics by 55.3% in the 1st quarter. Principal Financial Group Inc. now owns 631,260 shares of the company's stock valued at $5,359,000 after acquiring an additional 224,790 shares during the last quarter. Baker BROS. Advisors LP boosted its holdings in Bicycle Therapeutics by 15.8% during the fourth quarter. Baker BROS. Advisors LP now owns 10,885,357 shares of the company's stock worth $152,395,000 after buying an additional 1,485,397 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in Bicycle Therapeutics by 90.3% during the first quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company's stock worth $108,000 after buying an additional 6,057 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in Bicycle Therapeutics during the fourth quarter worth $614,000. Finally, Fcpm Iii Services B.V. boosted its holdings in Bicycle Therapeutics by 47.5% during the fourth quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company's stock worth $48,333,000 after buying an additional 1,112,369 shares in the last quarter. Hedge funds and other institutional investors own 86.15% of the company's stock.
About Bicycle Therapeutics
(
Get Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Featured Articles
Before you consider Bicycle Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.
While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
